These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 30396902)

  • 1. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
    Conway JR; Herrmann D; Evans TJ; Morton JP; Timpson P
    Gut; 2019 Apr; 68(4):742-758. PubMed ID: 30396902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
    Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
    Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
    Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
    Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
    Thillai K; Lam H; Sarker D; Wells CM
    Oncotarget; 2017 Feb; 8(8):14173-14191. PubMed ID: 27845911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
    Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
    J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mTOR dependency in pancreatic cancer.
    Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
    Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
    Alagesan B; Contino G; Guimaraes AR; Corcoran RB; Deshpande V; Wojtkiewicz GR; Hezel AF; Wong KK; Loda M; Weissleder R; Benes CH; Engelman J; Bardeesy N
    Clin Cancer Res; 2015 Jan; 21(2):396-404. PubMed ID: 25348516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAK and paxillin, two potential targets in pancreatic cancer.
    Kanteti R; Batra SK; Lennon FE; Salgia R
    Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
    McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
    Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
    De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
    Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E; Eibl G
    World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.